News
2d
Stocktwits on MSNThis Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
3d
TipRanks on MSNSarepta Therapeutics Announces Strategic Restructuring Plan
Sarepta Therapeutics ( ($SRPT) ) has shared an update. Sarepta Therapeutics announced a strategic restructuring and pipeline prioritization, ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...
Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...
Fintel reports that on May 14, 2024, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Perform to Outperform. As of May 8, 2024, the average one-year price target ...
Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT Provided by PR Newswire Jul 21, 2025, 8:15:00 AM ...
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the August 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results